Alpha 2.0
Login Register
» Authors » Raffael Nachbagauer

Raffael Nachbagauer

Explore the profile of Raffael Nachbagauer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 79
Citations 3288
Followers 0
Related Specialties
Science
General Medicine
Allergy & Immunology
Top 10 Co-Authors
Florian Krammer
Peter Palese
Daniel Stadlbauer
Adolfo Garcia-Sastre
Angela Choi
Alec W Freyn
Shirin Strohmeier
Randy A Albrecht
Fatima Amanat
Bruce L Innis
Published In
J Virol
mBio
Vaccines (Basel)
NPJ Vaccines
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults
Soens M, Ananworanich J, Hicks B, Lucas K, Cardona J, Sher L, et al.
Vaccine . 2025 Feb; 50:126847. PMID: 39919447
Background: Messenger RNA (mRNA)-based influenza vaccines have the potential to improve upon limitations of current vaccine approaches to seasonal influenza. Methods: Here we report findings on the primary and secondary...
2.
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens
El Sahly H, Anderson E, Jackson L, Neuzil K, Atmar R, Bernstein D, et al.
Vaccine . 2025 Jan; 47:126689. PMID: 39756216
Introduction: Pandemic influenza vaccine development focuses on the hemagglutinin (HA) antigen for potency and immunogenicity. Antibody responses targeting the neuraminidase (NA) antigen, or the HA stalk domain have been implicated...
3.
Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein
Malladi S, Jaiswal D, Ying B, Alsoussi W, Darling T, Dadonaite B, et al.
bioRxiv . 2024 Dec; PMID: 39713327
SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. It remains unclear how the continuous evolution of the virus impacts the breadth of the...
4.
An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus
Hatta M, Hatta Y, Choi A, Hossain J, Feng C, Keller M, et al.
Sci Transl Med . 2024 Dec; 16(778):eads1273. PMID: 39693411
The global spread of the highly pathogenic avian influenza (HPAI) A(H5N1) virus poses a serious pandemic threat, necessitating the swift development of effective vaccines. The success of messenger RNA (mRNA)...
5.
mRNA-based influenza vaccine expands breadth of B cell response in humans
Matz H, Yu T, Zhou J, Peyton L, Madsen A, Han F, et al.
bioRxiv . 2024 Oct; PMID: 39416092
Eliciting broad and durable antibody responses against rapidly evolving pathogens like influenza viruses remains a formidable challenge. The germinal center (GC) reaction enables the immune system to generate broad, high-affinity,...
6.
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial
Hsu D, Jayaraman A, Pucci A, Joshi R, Mancini K, Chen H, et al.
Lancet Infect Dis . 2024 Sep; 25(1):25-35. PMID: 39245055
Background: Inclusion of additional influenza A/H3N2 strains in seasonal influenza vaccines could expand coverage against multiple, antigenically distinct, cocirculating A/H3N2 clades and potentially replace the no longer circulating B/Yamagata strain....
7.
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial
Ananworanich J, Lee I, Ensz D, Carmona L, Schaefers K, Avanesov A, et al.
J Infect Dis . 2024 Jun; 231(1):e113-e122. PMID: 38934845
Background: Seasonal influenza remains a global public health concern. A messenger RNA (mRNA)-based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in a first-in-human, phase 1/2 clinical trial conducted in 3...
8.
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
Bliss C, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, et al.
EBioMedicine . 2024 May; 104:105153. PMID: 38805853
Background: The development of a universal influenza virus vaccine, to protect against both seasonal and pandemic influenza A viruses, is a long-standing public health goal. The conserved stalk domain of...
9.
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines
Russell C, Fouchier R, Ghaswalla P, Park Y, Vicic N, Ananworanich J, et al.
Hum Vaccin Immunother . 2024 Apr; 20(1):2336357. PMID: 38619079
Influenza remains a public health threat, partly due to suboptimal effectiveness of vaccines. One factor impacting vaccine effectiveness is strain mismatch, occurring when vaccines no longer match circulating strains due...
10.
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis
Lee I, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, et al.
Nat Commun . 2023 Jun; 14(1):3631. PMID: 37336877
Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of...